April - June 2011
May 11, 2011
Takeda Pharmaceutical Company Limited
Osaka, Japan, May 11, 2011—Takeda Pharmaceutical Company Limited (“Takeda”) announced today that it has nominated new director candidates and non-executive director candidates, and that it will present such nominations as the matter for resolution at the 135th Ordinary General Meeting of Shareholders scheduled on June 24, 2011.
Takeda is now aiming to become the global leader in the pharmaceutical industry by responding flexibly to changes in the operating environment so that it can achieve sustainable growth in the future. To this end, the Company will further pursue innovation and enhance its corporate governance, through inviting new directors, by actively introducing abundant experiences and a broad range of knowledge about the overall management of the company, pharmaceutical industry, as well as external view points, which is expected to inspire management.
At the 135th Ordinary General Meeting of Shareholders scheduled on June 24, the retirement of Mr. Makoto Yamaoka, Senior Managing Director of Takeda from his current position will be presented as the matter for resolution, and he will assume the presidency of Takeda’s wholly owned subsidiary, Takeda (China) Holdings Co., Ltd., being in charge of strengthening the company’s presence in China, that has the utmost importance for Takeda among rapidly growing emerging markets.
Guided by the Mission of “striving towards better health for patients worldwide through leading innovation in medicine,” Takeda will remain committed to bringing about “transformation into a new Takeda” to ensure sustainable business growth, thereby maximizing its corporate value.
# # #
1. New director candidates
|Frank Morich, MD, PhD||Takeda Pharmaceuticals International, Inc.
Executive Vice President, International Operations (Americas/Europe)
|Tadataka (Tachi) Yamada, MD||President of the Global Health Program,
Bill & Melinda Gates Foundation
Upon assumption of his new position, Tadataka (Tachi) Yamada, MD, currently a member of the Takeda Global Advisory Board (TGAB), will step down from the TGAB and take charge of duties concerning Takeda’s R&D decision-making process, such as chairmanship of the Management and Operations Committee that deliberates matters concerning R&D and Business Development.
2. Non-executive director candidates
|Fumio Sudo||Honorary Advisor, JFE Holdings, Inc.|
|Yorihiko Kojima||Chairman of the Board, Mitsubishi Corporation|
3. Retirement of a current director
Name: Makoto Yamaoka, Senior Managing Director
# # #
About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.